Study aim: Evaluation of the effect of Grapex on the alternations of clinical symptoms and laboratory findings in patients with coronary hospitalization in Abadan hospitals. Design: Clinical trial with control group, and parallel groups, double-blind, randomized, phase 3 on 80 patients Settings and conduct: investigation of clinical symptoms and laboratory findings due to use of Grapex on covid-12 patients in abadan hospitals. Patients and researchers are blinded as double blind. Include treatment and control groups. Control group: The patients receive county protocol with placebo Treatment group: The patients receive county protocol with Grapex 200 mg, twice a day for 2 weeks. The desired outcomes are compared before treatment and at the discharge time. Participants/Inclusion and exclusion criteria: COVID-19 patients that have positive PCR test COVID-19 patients that have positive by CT Scan for COVID-19. Exclusion criteria: Pregnant or breast feeding women, Patients under 18 years of age, Any life-threatening factor Intervention groups: Control group: The patients receive county protocol with placebo Treatment group: The patients receive county protocol with Grapex 200 mg, twice a day for 2 weeks. Main outcome variables: Time to clinical alternations defined as start of taking medication time to Discharge Time.